Expres2ion Biotechnologies announces positive results for its covid-19 vaccine
Copenhagen, December 2021 “ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that the ABNCoV2 vaccine demonstrated a strong boosting effect in the clinical Phase II trial conducted by Bavarian Nordic. ” Read more about the exciting news HERE. Expres2ion was Gemstone Capital’s first IPO (2016)